TY - JOUR
T1 - Immunotherapy for cardiovascular disease
AU - Lutgens, Esther
AU - Atzler, Dorothee
AU - Döring, Yvonne
AU - Duchene, Johan
AU - Steffens, Sabine
AU - Weber, Christian
N1 - Funding Information:
The Netherlands Organization for Scientific Research (NWO, VICI grant to E.L. 016.130.676); the EU (H2020-PHC-2015-667673, REPROGRAM to E.L. and D.A.); the European Research Council (ERC consolidator grant to E.L. CD40-INN 681492); ERC advanced grant (692511 to C.W.); and the German Centre for Cardiovascular Research (DZHK) high-risk high-volume (HRHV) grant to E.L, D.A., and C.W.
Funding Information:
This study was supported by the Deutsche Forschungsgemeinschaft (DFG CRC 1123 to E.L., D.A, Y.D., J.D., S.S., C.W). We acknowledge the support from the Netherlands CardioVascular Research Initiative: the Dutch Heart Foundation, Dutch Federation of University Medical Centres, the Netherlands Organisation for Health Research and Development and the Royal Netherlands Academy of Sciences for the GENIUS-II project.
Publisher Copyright:
© The Author(s) 2019.
PY - 2019/12/21
Y1 - 2019/12/21
N2 - The outcomes of the Canakinumab Anti-inflammatory Thrombosis Outcome Study (CANTOS) trial have unequivocally proven that inflammation is a key driver of atherosclerosis and that targeting inflammation, in this case by using an anti-interleukin-1b antibody, improves cardiovascular disease (CVD) outcomes. This is especially true for CVD patients with a pro-inflammatory constitution. Although CANTOS has epitomized the importance of targeting inflammation in atherosclerosis, treatment with canakinumab did not improve CVD mortality, and caused an increase in infections. Therefore, the identification of novel drug targets and development of novel therapeutics that block atherosclerosis-specific inflammatory pathways and exhibit limited immune-suppressive side effects, as pursued in our collaborative research centre, are required to optimize immunotherapy for CVD. In this review, we will highlight the potential of novel immunotherapeutic targets that are currently considered to become a future treatment for CVD.
AB - The outcomes of the Canakinumab Anti-inflammatory Thrombosis Outcome Study (CANTOS) trial have unequivocally proven that inflammation is a key driver of atherosclerosis and that targeting inflammation, in this case by using an anti-interleukin-1b antibody, improves cardiovascular disease (CVD) outcomes. This is especially true for CVD patients with a pro-inflammatory constitution. Although CANTOS has epitomized the importance of targeting inflammation in atherosclerosis, treatment with canakinumab did not improve CVD mortality, and caused an increase in infections. Therefore, the identification of novel drug targets and development of novel therapeutics that block atherosclerosis-specific inflammatory pathways and exhibit limited immune-suppressive side effects, as pursued in our collaborative research centre, are required to optimize immunotherapy for CVD. In this review, we will highlight the potential of novel immunotherapeutic targets that are currently considered to become a future treatment for CVD.
KW - Cardiovascular disease
KW - Coronary artery disease
KW - Inflammation
KW - Novel targets • cytokines
KW - Novel therapies
UR - http://www.scopus.com/inward/record.url?scp=85070321453&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85070321453&partnerID=8YFLogxK
U2 - 10.1093/eurheartj/ehz283
DO - 10.1093/eurheartj/ehz283
M3 - Review article
C2 - 31121017
AN - SCOPUS:85070321453
SN - 0195-668X
VL - 40
SP - 3937
EP - 3946
JO - European heart journal
JF - European heart journal
IS - 48
ER -